NCT01041040 2013-07-31LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)PETHEMA FoundationPhase 4 Completed200 enrolled